Evidence map›Paper›PMID 40775723›Full record

ArticleJournal of cheminformatics2025

Nanodesigner: resolving the complex-CDR interdependency with iterative refinement.

Melissa Maria Rios Zertuche, Şenay Kafkas, Dominik Renn, Magnus Rueping, Robert Hoehndorf

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melissa Maria Rios ZertucheBiological and Environmental Science and Engineering (BESE) Division, King Abdullah University of Science and Technology, 23955-6900, Thuwal, Saudi Arabia.
Şenay KafkasKAUST Beacon Development, King Abdullah University of Science and Technology, 23955-6900, Thuwal, Saudi Arabia.
Dominik RennKAUST Catalysis Center (KCC), Division of Physical Sciences and Engineering, King Abdullah University of Science and Technology, 23955-6900, Thuwal, Saudi Arabia.
Magnus RuepingKAUST Catalysis Center (KCC), Division of Physical Sciences and Engineering, King Abdullah University of Science and Technology, 23955-6900, Thuwal, Saudi Arabia.
Robert HoehndorfBiological and Environmental Science and Engineering (BESE) Division, King Abdullah University of Science and Technology, 23955-6900, Thuwal, Saudi Arabia. robert.hoehndorf@kaust.edu.sa.

Funding

King Abdullah University of Science and Technology URF/1/4675-01-01King Abdullah University of Science and Technology - Center of Excellence for Generative AI 5940King Abdullah University of Science and Technology - KAUST Center of Excellence for Smart Health (KCSH) 5932
6 · The paper itself

Abstract

Camelid heavy-chain only antibodies consist of two heavy chains and single variable domains (VHHs), which retain antigen-binding functionality even when isolated. The term "nanobody" is now more generally used for describing small, single-domain antibodies. Several antibody generative models have been developed for the sequence and structure co-design of the complementarity-determining regions (CDRs) based on the binding interface with a target antigen. However, these models are not tailored for nanobodies and are often constrained by their reliance on experimentally determined antigen-antibody structures, which are labor-intensive to obtain. Here, we introduce NanoDesigner, a tool for nanobody design and optimization based on generative AI methods. NanoDesigner integrates key stages-structure prediction, docking, CDR generation, and side-chain packing-into an iterative framework based on an expectation maximization (EM) algorithm. The algorithm effectively tackles an interdependency challenge where accurate docking presupposes a priori knowledge of the CDR conformation, while effective CDR generation relies on accurate docking outputs to guide its design. NanoDesigner approximately doubles the success rate of de novo nanobody designs through continuous refinement of docking and CDR generation.

Indexed as

Antibody designExpectation maximizationGenerative AINanobody design

Identifiers

PMID40775723
PMCPMC12333243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.